Not yet recruitingInterventionalPhase 2Last updated Aug 10, 2026

A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)

Overview

ClinicalTrials.gov ID: NCT07753824
Lead Sponsor: M.D. Anderson Cancer CenterOTHER
Brief Summary: To evaluate the safety and effectiveness of Ivonescimab combined with intraperitoneal paclitaxel (IP PTX) in patients with unresectable metastatic high-grade Appendiceal Adenocarcinoma (AA).
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Jan 16, 2027Estimated
Primary Completion Date: Nov 28, 2031Estimated
Completion Date: Nov 28, 2032Estimated

Study Record Dates

First Submitted: Aug 3, 2026
First Submitted that Met QC Criteria: Aug 3, 2026
First Posted: Aug 10, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 3, 2026
Last Update Posted: Aug 10, 2026Actual
Last Verified: Jul 2026

NCT07385001Recruiting

A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC

NCT07743138Not yet recruiting

STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)

NCT05039801Recruiting

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

NCT06953999Recruiting

A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer

NCT07244965Not yet recruiting

Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

NCT06415669Recruiting

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma